Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Micha, Levi"'
Autor:
Federico Reali, Anna Fochesato, Chanchala Kaddi, Roberto Visintainer, Shayne Watson, Micha Levi, Véronique Dartois, Karim Azer, Luca Marchetti
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2024)
Introduction: Understanding drug exposure at disease target sites is pivotal to profiling new drug candidates in terms of tolerability and efficacy. Such quantification is particularly tedious for anti-tuberculosis (TB) compounds as the heterogeneous
Externí odkaz:
https://doaj.org/article/43f89e564cbe44c49eaf849a38b5aefa
Autor:
Itay, Perlstein, Avia, Merenlender Wagner, Roberto, Gomeni, Michael, Lamson, Eran, Harary, Ofer, Spiegelstein, Attila, Kalmanczhelyi, Ryan, Tiver, Pippa, Loupe, Micha, Levi, Anna, Elgart
Publikováno v:
Clinical Pharmacology in Drug Development. 11:865-877
TV-46000 is a long-acting subcutaneous antipsychotic that uses a novel copolymer drug delivery technology in combination with a well-characterized molecule, risperidone, that is in clinical development as a treatment for schizophrenia. A population p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25cc3216f9f60cc6cdd980c2454bc0e8
https://doi.org/10.1002/cpdd.1078
https://doi.org/10.1002/cpdd.1078
Publikováno v:
Headache
Objective Exposure-response (E-R) models were developed to provide a description of the time-course of treatment effect for monthly and quarterly dosing regimens of fremanezumab. Background Fremanezumab is a monoclonal antibody for preventive treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fecccc37e6d1b220a5dfb1d5ddca1635
https://doi.org/10.1111/head.13845
https://doi.org/10.1111/head.13845
Autor:
Andrijana Radivojevic, Pippa S. Loupe, Michael Brennan, Xiaoping Ning, Michael Gillespie, Orit Cohen-Barak, Andrew H. Ahn, Yoel Kessler, Aksana Jones, Michele Rasamoelisolo, Laura Rabinovich-Guilatt, Jill Fiedler-Kelly, Dikla Gutman, Micha Levi, Hussein Hallak
Publikováno v:
Cephalalgia : an international journal of headache. 41(10)
Background Potential fremanezumab doses for pediatric patients were evaluated using pharmacokinetic modeling and simulation. An open-label phase 1 pharmacokinetic and safety study was conducted in pediatric patients with migraine. This study’s resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52808ded1741d75d6d3addb117322f06
https://pubmed.ncbi.nlm.nih.gov/34000848
https://pubmed.ncbi.nlm.nih.gov/34000848
Autor:
Libin Rong, Jeremie Guedj, Harel Dahari, Daniel J Coffield, Micha Levi, Patrick Smith, Alan S Perelson
Publikováno v:
PLoS Computational Biology, Vol 9, Iss 3, p e1002959 (2013)
The current paradigm for studying hepatitis C virus (HCV) dynamics in patients utilizes a standard viral dynamic model that keeps track of uninfected (target) cells, infected cells, and virus. The model does not account for the dynamics of intracellu
Externí odkaz:
https://doaj.org/article/fc3a932b93274776ae3558a58bbb938d
Autor:
Hooman Beygi, Igor D. Grachev, Juha-Matti Savola, Micha Levi, Serge Guzy, Margaret Bradbury, Pippa S. Loupe, Lavi Erisson, Ofer Spiegelstein, Maria Velinova, Spyros Papapetropoulos, William Tracewell, Mirna McDonald, Orit Cohen-Barak, Frank Schneider
Publikováno v:
British Journal of Clinical Pharmacology. 84:2422-2432
AIMS SD-1077, a selectively deuterated precursor of dopamine (DA) structurally related to L-3,4-dihydroxyphenylalanine (L-DOPA), is under development for treatment of motor symptoms of Parkinson's disease. Preclinical models have shown slower metabol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66afb0fc32dce1d2a72c8a6e5722f9e3
https://doi.org/10.1111/bcp.13702
https://doi.org/10.1111/bcp.13702
Autor:
Jill Fiedler-Kelly, Micha Levi, Julie A. Passarell, Margaret Garin, Mary Bond, David Jaworowicz, Laura Rabinovich-Guilatt, Elizabeth Ludwig, Donna S. Cox
Publikováno v:
Journal of clinical pharmacologyReferences. 60(8)
Reslizumab 3.0 mg/kg has demonstrated efficacy in clinical studies of patients with eosinophilic asthma and a history of exacerbations. A population pharmacokinetic (PK) model was developed to determine whether 3.0 mg/kg weight-based dosing is approp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f09ceba2b6f9066591639e0cee1c3259
https://pubmed.ncbi.nlm.nih.gov/32333684
https://pubmed.ncbi.nlm.nih.gov/32333684
Autor:
Michele Rasamoelisolo, Orit Cohen-Barak, Honglue Shen, Denise N Morris, Elizabeth Ludwig, Jill Fiedler-Kelly, Micha Levi
Publikováno v:
British Journal of Clinical Pharmacology
Aims Fremanezumab is a fully humanized IgG2 Δa/κ monoclonal antibody specific for calcitonin gene-related peptide developed and approved for the preventive treatment of migraine in adults. The population pharmacokinetics (PK) of fremanezumab were c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b91975af751a2a94763f4b9ffb1c463
https://pubmed.ncbi.nlm.nih.gov/31418911
https://pubmed.ncbi.nlm.nih.gov/31418911
Autor:
Harm Peters, Ricardo L. Chaves, Micha Levi, Natascia Corti, Dmytro Khadzhynov, Kamal Hamed, Xiaoying Xu
Publikováno v:
British Journal of Clinical Pharmacology. 83:498-509
Aim The objective of this population pharmacokinetic (PK) analysis was to provide guidance for the dosing interval of daptomycin in patients undergoing continuous renal replacement therapy (CRRT). Methods A previously published population PK model fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9e46512d47a160f3da564828898d374
https://doi.org/10.1111/bcp.13131
https://doi.org/10.1111/bcp.13131
Autor:
Frank, Schneider, Lavi, Erisson, Hooman, Beygi, Margaret, Bradbury, Orit, Cohen-Barak, Igor D, Grachev, Serge, Guzy, Pippa S, Loupe, Micha, Levi, Mirna, McDonald, Juha-Matti, Savola, Spyros, Papapetropoulos, William G, Tracewell, Maria, Velinova, Ofer, Spiegelstein
Publikováno v:
British journal of clinical pharmacology. 84(10)
SD-1077, a selectively deuterated precursor of dopamine (DA) structurally related to L-3,4-dihydroxyphenylalanine (L-DOPA), is under development for treatment of motor symptoms of Parkinson's disease. Preclinical models have shown slower metabolism o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a79b98d8baa7e8ab3ceb6e5e17bd386f
https://pubmed.ncbi.nlm.nih.gov/29959802
https://pubmed.ncbi.nlm.nih.gov/29959802